PL2242769T3 - Przeciwciała przeciw domenie ec1 kadheryny 11 do leczenia zapalnych zaburzeń stawów - Google Patents

Przeciwciała przeciw domenie ec1 kadheryny 11 do leczenia zapalnych zaburzeń stawów

Info

Publication number
PL2242769T3
PL2242769T3 PL09700394T PL09700394T PL2242769T3 PL 2242769 T3 PL2242769 T3 PL 2242769T3 PL 09700394 T PL09700394 T PL 09700394T PL 09700394 T PL09700394 T PL 09700394T PL 2242769 T3 PL2242769 T3 PL 2242769T3
Authority
PL
Poland
Prior art keywords
cadherin
domain antibodies
treating inflammatory
inflammatory joint
joint disorders
Prior art date
Application number
PL09700394T
Other languages
English (en)
Polish (pl)
Inventor
James G. Mcarthur
Original Assignee
Adheron Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adheron Therapeutics, Inc. filed Critical Adheron Therapeutics, Inc.
Publication of PL2242769T3 publication Critical patent/PL2242769T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL09700394T 2008-01-11 2009-01-09 Przeciwciała przeciw domenie ec1 kadheryny 11 do leczenia zapalnych zaburzeń stawów PL2242769T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1073408P 2008-01-11 2008-01-11

Publications (1)

Publication Number Publication Date
PL2242769T3 true PL2242769T3 (pl) 2017-06-30

Family

ID=40602259

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09700394T PL2242769T3 (pl) 2008-01-11 2009-01-09 Przeciwciała przeciw domenie ec1 kadheryny 11 do leczenia zapalnych zaburzeń stawów

Country Status (15)

Country Link
US (4) US8591888B2 (enExample)
EP (2) EP3181588A1 (enExample)
JP (1) JP5511684B2 (enExample)
CN (1) CN101952316B (enExample)
AU (1) AU2009204467B2 (enExample)
BR (1) BRPI0906492A2 (enExample)
CA (1) CA2711394A1 (enExample)
DK (1) DK2242769T3 (enExample)
ES (1) ES2611102T3 (enExample)
HU (1) HUE031207T2 (enExample)
IL (1) IL206880A (enExample)
MX (1) MX2010007551A (enExample)
PL (1) PL2242769T3 (enExample)
SI (1) SI2242769T1 (enExample)
WO (1) WO2009089062A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007551A (es) * 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
EP3138915A1 (en) * 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
BR112013001062A2 (pt) * 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
KR20130142025A (ko) * 2012-06-18 2013-12-27 한국생명공학연구원 카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US10435452B2 (en) 2015-05-29 2019-10-08 Children's Hospital Medical Center Cadherin 26 (CDH26)-Fc fusion proteins and methods of use thereof to treat inflammatory conditions
KR101654526B1 (ko) * 2015-10-19 2016-09-06 한국생명공학연구원 카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US253200A (en) * 1882-02-07 Timothy guilford
US215482A (en) * 1879-05-20 Improvement in spring be d-bottoms
US229811A (en) * 1880-07-13 dtjnlop
US248219A (en) * 1881-10-11 Panorama-toy
US248220A (en) * 1881-10-11 Machine for graining and dicing leather
US110755A (en) * 1871-01-03 Improvement in spike-machines
US229199A (en) * 1880-06-22 Wood-working machine
US8323A (en) * 1851-08-26 colne
US96746A (en) * 1869-11-09 Improvement in mechanical movements
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US5859136A (en) * 1997-11-03 1999-01-12 E. I. Du Pont De Nemours And Company Coating composition containing an amine functional dispersed polymer and an isocyanate curing agent
US6638911B1 (en) 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
AU759144B2 (en) * 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
ES2592507T3 (es) 1999-09-03 2016-11-30 The Brigham And Women's Hospital, Inc. Métodos y composiciones para el tratamiento de enfermedad inflamatoria mediante el uso de agentes moduladores de cadherina-11
US20040110755A1 (en) * 2002-08-13 2004-06-10 Boehringer Ingelheim Pharmaceuticals, Inc. Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US6952969B2 (en) * 2003-09-30 2005-10-11 The Aerospace Corporation Ceramic ball bearing fracture test method
WO2006089397A1 (en) * 2005-02-22 2006-08-31 Gemin X Biotechnologies Inc. Methods for treating arthritis using triheterocyclic compounds
MX2010007551A (es) 2008-01-11 2010-11-30 Synovex Corp Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion.
CN101998966A (zh) 2008-02-11 2011-03-30 诺瓦提斯公司 使用钙黏着蛋白11(cdh11)拮抗剂的方法
CN102753579A (zh) * 2009-05-01 2012-10-24 国立大学法人东京大学 抗钙粘着蛋白抗体
BR112013001062A2 (pt) 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados

Also Published As

Publication number Publication date
JP5511684B2 (ja) 2014-06-04
EP3181588A1 (en) 2017-06-21
AU2009204467A1 (en) 2009-07-16
SI2242769T1 (sl) 2017-02-28
CN101952316B (zh) 2015-04-01
US20140120104A1 (en) 2014-05-01
EP2242769A2 (en) 2010-10-27
WO2009089062A2 (en) 2009-07-16
EP2242769B1 (en) 2016-11-02
DK2242769T3 (en) 2017-02-06
WO2009089062A3 (en) 2009-09-24
BRPI0906492A2 (pt) 2015-12-01
US9315568B2 (en) 2016-04-19
HUE031207T2 (hu) 2017-07-28
CN101952316A (zh) 2011-01-19
ES2611102T3 (es) 2017-05-04
MX2010007551A (es) 2010-11-30
IL206880A (en) 2014-12-31
WO2009089062A8 (en) 2010-09-02
US7972846B2 (en) 2011-07-05
US20110045003A1 (en) 2011-02-24
IL206880A0 (en) 2010-12-30
US20110008323A1 (en) 2011-01-13
JP2011509094A (ja) 2011-03-24
US8591888B2 (en) 2013-11-26
AU2009204467B2 (en) 2012-09-06
CA2711394A1 (en) 2009-07-16
US20090253200A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
SI2242769T1 (sl) Protitelesa anti-kadherin-11 EC domene za zdravljenje vnetnih obolenj sklepov
EP2296653A4 (en) COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS
IL257418A (en) Methods for treating addiction
EP2309858A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
ZA200807015B (en) Dihydrothienopyrimidine for treating inflammatory disorders
EP2331088A4 (en) COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
IL211587A0 (en) Treating inflammatory conditions
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
IL241791A0 (en) Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
EP2349079A4 (en) CHARGER FOR AN IMPLANT
IL212986A0 (en) Methods for treating eye disorders
GB2467710B (en) Methods for treating social disorders
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
WO2011044264A9 (en) Pyrrolopyrazoles for treating cns disorders
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
EP2351457A4 (en) CREATING TECHNOLOGY-BASED CONFIGURATION SETTINGS
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
PL2269058T3 (pl) Sposób charakteryzowania odporności paliw na stukanie
EP2318436A4 (en) ANTIBODIES OF DIFFERENT DOMAINS
EP2321379A4 (en) METHOD FOR IMPROVING THE TRANSFER PROPERTIES OF BITUMEN
HU0800156V0 (en) Improved aid for facilitate the moving of cables in culverts
EP2219650A4 (en) COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS
IL207906A0 (en) Treatment for ocular-related disorders
AU2009223851A8 (en) Methods of treating hyperacidic disorders
GB0812805D0 (en) Shower rail